Dr. Loralie Langman has been a Clinical Biochemist for 25 years and has been working as part of the medical laboratory team for over 35 years. She is the 2025 recipient of the Canadian Society of Clinical Chemists (CSCC) Outstanding Contribution to Clinical Chemistry, an award presented as a mark of recognition of outstanding achievement in and/or contribution to the field of clinical chemistry. Dr. Langman is an exceptional character who has contributed immensely to our profession in many facets, and her contributions are truly outstanding.

Dr. Langman is a true leader, a mentor and collaborator. Her character has often been shown over the years during our formal events with the many different and inspiring hats she has worn. At the same time, Dr. Langman engages in multifaceted aspects of our profession, as she figuratively wears many “hats” through her work as a certified Clinical Biochemist (CACB and ABCC), Toxicologist (ABCC), Forensic Toxicologist (ABFT) and Molecular Diagnostics (ABCC). She has also continued her active certification as a medical laboratory technologist.

Dr. Langman has received numerous awards throughout her career, such as the Award for Outstanding Scientific Achievements by a Young Investigator (Association for Diagnostics & Laboratory Medicine [ADLM]; formerly American Association for Clinical Chemistry), Service Award (Clinical and Laboratory Standards Institute (CLSI)), Research Excellence Award (CSCC), Professor Alvin Dubin Award for Outstanding Contributions to the Profession and the Academy (ADLM), and the Irving Sunshine Award for Outstanding Contributions to Clinical Toxicology (International Association of Therapeutic Drug Monitoring and Clinical Toxicology [IATDM]).

Service to her community is a very important part of the work that Dr. Langman does. She has served countless hours on numerous committees, boards and societies. Her commitment has spanned locally, nationally and internationally, and briefly includes some of the following roles. She has shown immense support to CSCC through councillor, annual meetings participation, education & public outreach. and toxicology interest group involvement, alongside Canadian Academy of Clinical Biochemistry (CACB) syllabus update reviews. She also has had numerous ADLM annual meetings and board committee roles, Alberta Society for Human Toxicology participation, American Academy of Forensic Sciences committee chair and member roles, and CLSI committee member, council and board of director roles. Further afield, she has been an IATDM member, councillor, board and congress organization role, and has held International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) committee member and chair roles.

Dr. Langman also has an immense passion for teaching and education, as exemplified by her numerous accomplishments. She has supported curriculum developed within Mayo Clinic College of Medicine, IFCC and CSCC. She has numerous teaching duties, such as those with the Department of Laboratory Medicine and Pathology Chemistry (Rochester, Minnesota), Clinical Biochemistry & Immunology Clinical Core Laboratory Services Biochemical Genetics (Rochester, Minnesota), and Mayo Medical School (Rochester, Minnesota). She also engages in additional academic development through education oversight, grand rounds planning, and graduate medical education support.

Academically, Dr. Langman has made invaluable contributions, with 98 peer-reviewed articles, in addition to 32 different book chapters, 91 abstracts, and several non-peer reviewed articles, editorials, commentaries, audio/visual resources. She has presented at numerous local, national and international events in areas ranging from lab challenges, pharmacogenetics, therapeutic drug monitoring, to new technology, toxicology screening, pain management and postmortem toxicology.

A special area of recognition has been her exceptional work as editor-in-chief of Clinical Biochemistry. During the challenging and unprecedented “COVID years,” her leadership became even more critical. The pandemic presented unique obstacles, not only to the clinical biochemistry community, but also the world of publishing. Dr. Langman adapted to these challenges by continuing to ensure timely publication of high-quality papers and helped maintain the journal’s standards. She has been a highly committed and exceptional leader in paving the course of the journal over the past several years.

Despite many of Dr. Langman’s significant contributions spanning both international platforms and within the United States, she remains professionally rooted in her Canadian identity. Her dedication to the CSCC and the laboratory medicine community in Canada is a testament to her unwavering commitment to the profession of clinical biochemists in Canada. Dr. Langman is a global citizen yet carries with her the values and pride of being a Canadian and devoted member of CSCC.

1. The Award shall be presented as a mark of recognition of outstanding achievement in and/or contribution to the field of clinical chemistry.
2. The Award shall usually be presented annually, but if in the opinion of the Awards Committee no suitable candidate is available in any year, the Award shall not be made.
3. Siemens has agreed to make an annual contribution of $3,000 CDN to sponsor this award. A framed certificate and an honorarium in the amount of $1,500 shall accompany the Award. The balance of $1,500 remaining after the honorarium shall be used to meet the administrative expenses, the production of the framed scroll, and to make a contribution towards expenses involved in ensuring the attendance of the recipient at the Annual Conference of the Society.
4. The Awards Committee shall choose the recipient of the Award.
5. The Awards Committee shall report its choice to the Council of the Society at its Winter Meeting in the year for which the Award is made.
6. The President of the Society will notify the recipient(s) of the award and inform Siemens Inc. of the name of the recipient(s) of the Award not later than March 1, in the year for which the Award is made.   7. The recipient of the Award is not usually expected to give an address or give a paper, but the Award and the reading of the citation shall usually be made at the Annual Conference of the Society.  A representative of Siemens shall be invited to participate in the presentation.
7. No formal nomination procedure is specified, but members of the Society may propose suitable candidates to the Awards Committee through the Head Office of the Society.  Curriculum vitae and other suitable documentation in support of the nominee must accompany nominations from the membership.  Proposals shall be solicited annually in the Newsletter of the Society.
8. The amendment of these Terms of Reference is the responsibility of the Council, subject to the concurrence of the sponsor of the Award.  Council of the Society and the corporate sponsor of this award should review these terms of reference a minimum of once every 5 years.

The CSCC Award for Innovation in Laboratory Medicine is presented to a clinical laboratory in Canada that has distinguished itself by outstanding accomplishment through innovation in the field of clinical chemistry, pathology, or laboratory medicine. The 2025 recipient is the GENCOV research study.

The GENCOV study brought together highly skilled teams of clinicians, laboratory professionals and researchers, and it was extensively driven by laboratory data to understand the pathobiology of COVID-19. This multi-year interdisciplinary study ultimately led to an innovative risk score that can transform clinical practice. More specifically, it had a novel study protocol that involved implementation of serological and molecular tools from clinical laboratories and was able to identify critical characteristics of antibody responses, the role of genetic differences in infection severity, and the impact of viral lineages on patient response. Additionally, the study assessed patient-reported outcomes to evaluate the communication and understanding of complex SARS-CoV-2 test results.

The GENCOV study had 3 primary goals outlined below:

1. Identify factors influencing COVID-19 severity and immune response.
2. Identify gaps and strategies to improve public understanding of SARS-CoV-2 test results.
3. Create a framework for returning genomic and antibody results to patients.
4. Disseminate findings to inform public health and clinical practice.

Key findings of GENCOV included identifying patient factors and clinical biochemistry markers associated with hospitalization and mortality to inform the development of a laboratory-based risk score to predict mortality in hospitalized patients. It also contributed to the COVID-19 Host Genetic Initiative by identifying 51 genome-wide loci associated with COVID-19 severity and susceptibility. The engagement with the public was a unique and beneficial outcome as it helped to empower public understanding of complex test results. The work in this study brings positive visibility of lab medicine professionals, and it offers an opportunity to apply improvements for clinical laboratories to optimize return of all laboratory results.

This study involved several clinical laboratories that provided the technical expertise and infrastructure necessary for its success. This included Mount Sinai Hospital’s clinical microbiology and biochemistry laboratories that performed PCR and serological testing. Other hospital and community laboratories (Dynacare, William Osler, Mackenzie Health, The Hospital for Sick Children) were involved in biochemistry testing, viral sequencing, genetic sequencing or ancestry estimations. Research laboratories at University Health Network and Lunenfeld Tanenbaum Institute facilitated HLA genotyping and antibody profiling respectively. The clinical laboratories at Mount Sinai Hospital (clinical microbiology, genetics, biochemistry) collaborated with bioinformaticians and clinicians to integrate genomic and clinical datasets, facilitating the discovery of genetic loci influencing COVID-19 severity and immune responses. It also led the implementation of a return-of-results framework, integrating genomic and antibody data with clinical counseling to improve patient understanding of laboratory results and engagement. The lab team involved not only provided this substantial technical expertise but were instrumental in the 8 different publications and over 30 presentations to help in disseminating study findings.

The teams’ leadership in innovation, standardization, and collaboration established the GENCOV study as a model of excellence in laboratory medicine. It also provided transformative advantages to Mount Sinai Hospital and the University of Toronto by strengthening its reputation as leaders in cutting-edge research and innovation. The study’s success also elevated the profile of the principal investigator, Dr. Jennifer Taher, who was invited to join a $19-million pandemic preparedness research study based out of Mount Sinai Hospital as the sole representative clinical biochemist. This further highlights the value of clinical lab medicine, and specifically clinical biochemistry in supporting impactful lab medicine research. Dr. Taher, in part due to her successful role in GENCOV, was recognized as one of Canada’s Most Powerful Women in 2023.

Congratulations to Dr. Jennifer Taher (principal investigator), Dr. Steven Friedman (co-investigator), and the entire GENCOV team for the success of their research study.

1. The Award shall be presented to a Clinical Laboratory in Canada that has distinguished itself by outstanding accomplishment through innovation in the field of Clinical Chemistry, or Pathology and Laboratory Medicine for projects where a CSCC member was directly involved. This award is intended to encourage and recognize excellence in Clinical Laboratory Services especially in the role of improving the quality of health care, improving patient outcomes, and promoting a positive public image to clinical laboratories and laboratory professionals.
2. Eligible organizations for this award include:
   1. Private, Academic and Government Clinical Laboratories and Laboratory divisions.
   2. Rural and Regional Clinical Laboratories and Clinical Laboratory Departments.
3. Laboratories demonstrating outstanding accomplishments in one or more of the following areas completed within the last two calendar years are eligible for consideration:
   1. Innovation in strategic planning and implementation of laboratory services based on best practices.
   2. Innovation in development of new laboratory programs (e.g. new tests, facilities, and changes in practice).
   3. Innovation in teaching and education. 3.4. Promotion of a positive public image for laboratory medicine.
4. Nominations for this award will be received from members of the CSCC to the Awards Committee through the Head Office of the Society. Nominations for this award will include:
   1. A summary of the accomplishment(s) of the nominated organization with supporting documentation.
   2. A letter of support from a CSCC member involved in the project for which the organization is being nominated.
   3. A letter of support from the nominee’s organization administrative team (Signed by a Department Director, VP, or CEO).
5. Nominees having received this award within the last 3 years will not be eligible to receive this award for a current year.
6. Nominations for this award shall be solicited annually in the Newsletter of the Society.
7. The Award shall usually be presented annually, but if in the opinion of the Awards Committee there is no suitable candidate(s) available in any year, the Award shall not be made.
8. The Awards Committee shall select one of the nominees for the Award for recommendation to Council of the Society.
9. The Awards Committee shall report its recommendation to the Council of the Society for approval at its Winter Council meeting in the year for which the Award is to be made.
10. The President of the Society will notify the recipient organization of the Award and inform Roche Diagnostics of the name of the recipient of the award, not later than March 1 in the year in which the Award is made.
11. The CSCC supporting member and a representative from the administration of hospital or institution represented in the project will be invited to accept the award (display item) at the CSCC Annual Meeting. The award will be presented by a representative from Roche Diagnostics. The award will cover airfare, accommodation and expenses for 2 nights for both recipients, as per the CSCC Travel Guidelines. The intent is for CSCC to support the primary applicant to attend. If there are co-lead(s), then the primary applicant is to determine if/how funds will be shared. The expectation is that the CSCC would support the applicant in finding an administrator (clinical or operational) to receive the award.
12. The recipient of the Award is not usually expected to give an address, but the Award and the reading of the citation shall usually be made at the Annual Conference of the Society.
13. The amendment of these Terms of Reference is the responsibility of the Council, subject to the concurrence of the donor of the Award and should be reviewed at least every five years.

CSCC Award for Innovation in Laboratory Medicine – application form

Dr. Lawrence de Koning is the recipient of the 2025 CSCC Award for Research Excellence. This award is presented to an individual or group as a mark of recognition of their contribution to research directly or indirectly related to clinical chemistry in Canada.

Dr. de Koning has contributed significantly to the field of clinical biochemistry in Canada. He is recognized as a passionate advocate for clinical biochemists’ roles in research, innovation, and patient care. He is currently an Associate Professor at the University of Calgary and a Clinical Biochemist with Alberta Precision Laboratories in Calgary, Alberta. He completed a PhD in Health Research Methodology (nutritional and genetic epidemiology) from McMaster University in 2009, and concurrent postdoctoral fellowships in nutritional epidemiology and clinical chemistry at Harvard University from 2009-2012. He became board certified by the American Board of Clinical Chemistry in 2013 and a fellow of the Canadian Academy of Clinical Biochemistry in 2015. Dr. de Koning has been directing the pediatric clinical biochemistry testing laboratory at Alberta Children’s Hospital in Calgary, Alberta, Canada since 2012.

Dr. de Koning is passionate about novel biochemical markers for dietary intake and inflammation, and assessing their impact on cardiovascular risk. He has published several high impact articles on abdominal obesity and dietary patterns that have received media coverage. He is also driven by lab quality improvement and pediatric clinical biochemistry. He has 76 peer-reviewed papers, 79 conference presentations, and 2 book chapters, and has shared his knowledge at over 70 presentations. His research contributions focus on clinical biochemistry and data science to solve problems in maternal health and all areas of pediatric medicine, and he engages in epidemiologic investigations to help find innovative solutions.

Dr. de Koning has been successful throughout his research career at securing grant funding for his research, both on his own and in collaboration with others. He engages in mentoring young researchers, such as clinical biochemistry fellows, medical residents, and medical laboratory technologists. He also works to mentor colleagues within their clinical research and continues to encourage many across his teams to build their involvement in lab medicine research through collaborative projects and publications. He is a faculty member of the University of Calgary / Alberta Precision Laboratories Clinical Biochemistry Fellowship Program, an active mentor in the University of Calgary Bachelor of Health Sciences Mentorship program, and he has been a member of several graduate supervisory committees.

Although research is a passion for Dr. de Koning, he is also heavily involved in demanding clinical service. His comprehensive knowledge, understanding, and experience supports solving challenging clinical investigations, fosters positive relationships with other healthcare providers, and ultimately enhances the clinical biochemistry profession. Dr. de Koning further supports the field of clinical biochemistry professionally at the local and national level, including through his roles with the CSCC (previous Councillor; current Co-Chair of the Pediatric and Perinatal Biochemistry Special Interest Group), the Alberta Association of Clinical Laboratory Doctoral Scientists (AACLDS; current Chair), and the Alberta Society of Clinical Chemists (ASCC; Past President, Past Secretary). He also supports numerous activities within the Association for Diagnostics and Laboratory Medicine (ADLM), the University of Calgary, and is an active peer reviewer for multiple journals.

1. The Award shall be presented to an individual or group, as a mark of recognition of their contribution to research directly or indirectly related to clinical chemistry in Canada.
2. The Award shall usually be presented annually, but if in the opinion of the Awards Committee no group or individual is available in any year, the Award shall not be made.
3. Ortho-Clinical Diagnostics have agreed to make an annual contribution of $3,000 CDN. The Award shall be accompanied by a framed certificate and by an honorarium in the amount of $1,500. The balance of $1,500 remaining after the honorarium shall be used to meet the administrative expenses, the production of the framed scroll, and to make a contribution towards expenses involved in ensuring the attendance of the recipient at the Annual Conference of the Society.
4. The Awards Committee shall choose the recipient(s) of the Award.
5. The Awards Committee shall report its choice to the Council of the Society at its Winter Meeting for the year for which the Award is made.
6. The President of the Society will notify the recipient(s) of the award and inform Ortho Clinical Diagnostics of the name of the recipient(s) of the Award not later than March 1, in the year for which the Award is made. . 7. The recipient(s) of the Award is (are) not usually expected to give an address or present a paper, but the Award and the reading of the citation shall usually be made at the Annual Conference of the Society.  A representative of Ortho-Clinical Diagnostics shall be invited to participate in the presentation.
7. No formal nomination procedure is specified, but members of the Society may propose suitable candidates to the Awards Committee through the Head Office of the Society.  Curriculum vitae and other suitable documentation in support of the nominee must accompany nominations from the membership.  Proposals shall be solicited annually in the Newsletter of the Society.
8. The amendment of these Terms of Reference is the responsibility of the Council of the Society, subject to the concurrence of the sponsor of the Award.  Council of the Society and the corporate sponsor of the Award should review these Terms of Reference a minimum of once every five years.

Dr. Cynthia Balion is the recipient of the 2025 CSCC Award for Education Excellence. This award is presented to an individual or group as a mark of recognition of outstanding contribution to education in the field of clinical chemistry.

Dr. Balion is a Clinical Biochemist at Hamilton Health Sciences and the Program Director for the Clinical Biochemistry program at McMaster University. She is an Associate Professor, Department of Pathology and Molecular Medicine, Faculty of Health Sciences, and an Associate Member, Department of Health Research Methods, Evidence, and Impact, Faculty of Heath Science at McMaster University. She is a Fellow of the Canadian Academy of Clinical Biochemistry. She has made exceptional contributions to the education of Clinical Biochemistry fellows at McMaster University.

Dr. Balion has significantly contributed to the learning environment and the fellowship experience for clinical biochemistry fellows. She worked tirelessly to increase the salary for McMaster Clinical Biochemistry Fellows, advocating for better recognition of the fellows’ efforts in healthcare services. Furthermore, Dr. Balion addressed long-standing issues with the McMaster Clinical Biochemistry Diploma that did not accurately reflect the degree earned. She also ensured that fellows had access to dedicated study rooms in each of the four hospitals for rotations to create an ideal environment for learning.

Many clinical biochemists have had the pleasure of training with and being mentored by Dr. Balion. She encourages learners to engage in hands-on research projects and practical experiences, takes immense amounts of time to teach complex topics to both learners and lab staff, and engages in seeking feedback for opportunities to improve training. She fosters an open environment to discuss academic and personal challenges that leads to continuous improvement opportunities. Despite her demanding schedule, she always makes herself available for support, offering guidance to learners and lab staff whenever needed.

Dr. Balion has left an ineradicable mark on the professional development of fellows, through her exceptional dedication or education. Her kind approach and ability to be nurturing while providing an inclusive learning environment is commendable. Her commitment to fostering growth and confidence in her trainees is unparalleled. Through her value in engaging with current literature and practice guidelines to critically appraising and challenging current standards, she is able to instill the value and direction for process and quality improvements. Teaching future clinical biochemists is no small task, and Dr. Balion continues to do so this with grace, positive vision and kindness to support very successful careers.

Dr. Balion’s mentor and education role extends to sharing her insights and knowledge in publications, at conferences, and through other collaborative opportunities with colleagues. She has held numerous roles with the Canadian Society of Clinical Chemists (CSCC), Canadian Academy of Clinical Biochemistry (CACB) and the Ontario Society of Clinical Chemists (OSCC) to enable further mentorship and has shared her knowledge through numerous lectures and supervisorship at the undergraduate, graduate and post-graduate level at McMaster University.

The Award shall be presented to an individual or group as a mark of recognition of outstanding contribution to education in the field of clinical chemistry.

2. The Award shall usually be presented annually, but if in the opinion of the Awards Committee no suitable candidate is available in any year, the Award shall not be made.
3. Beckman Coulter Canada Inc. have committed to an annual contribution of $3,000 CDN. A framed certificate and an honorarium in the amount of $1,500 shall accompany the Award.  The balance of $1,500 remaining after the honorarium shall be used to meet the administrative expenses, the production of the framed scroll and to make a contribution towards the expenses involved in ensuring the attendance of the recipient at the Annual Conference of the Society.
4. The Awards Committee shall choose the recipient(s) of the Award.
5. The Awards Committee shall report its choice to the Council of the Society at its Winter Meeting in the year for which the Award is made.
6. The President of the Society will notify the recipient(s) of the award and inform Beckman Coulter Canada Inc. of the name of the recipient(s) of the Award not later than March 1, in the year for which the Award is made.
7. The recipient(s) of the Award is (are) not usually expected to give an address or present a paper, but the Award and the reading of the citation shall usually be made at the Annual Conference of the Society.  Representatives of Beckman Coulter Canada Inc. shall be invited to participate in the presentation.
8. No formal nomination procedure is specified, but members of the Society may propose suitable candidates to the Awards Committee through the Head Office of the Society. Curriculum vitae and other suitable documentation in support of the nominee must accompany nominations from the membership. Proposals shall be solicited annually in the Newsletter of the Society.
9. The amendment of these Terms of Reference is the responsibility of the Council, subject to the concurrence of the sponsor of the Award.  The CSCC Council and the corporate sponsor of the Award should review these Terms of Reference a minimum of once every five years.

ELIGIBILITY REQUIREMENTS
1. Applicants must be members of the CSCC.
2. Applicants must be enrolled EITHER in a CACB-accredited clinical biochemistry training program OR in a Royal College of Physicians and Surgeons of Canada-accredited medical biochemistry training program.

ADDITIONAL REQUIREMENTS
1. The Host Laboratory must perform clinical service in biochemistry, hematology, microbiology, immunology, genetics, and/or a related area.
2. The Host Laboratory must be located outside of the home city of the Applicant’s training program.
3. Funds must be used within one year of being awarded or before completion of the training program, whichever is earlier.
4. Successful Applicants must submit a summary article of their visit to CSCC News before completion of their training program. The article should describe goals that were achieved during the visit and how Applicants plan to apply their new knowledge in the future. Applicants should coordinate the length and timing of their articles with the Editor in Chief of the publication.

APPLICATION PROCESS
The applicant is to submit an online application via the CSCC website. Applications are accepted on an on-going basis throughout the year.

AWARDING OF GRANTS
CSCC Head Office will forward all applications to the Head of CSCC Professional Affairs Division (PAD) who will then appoint up to three (3) reviewers per application. All reviewers are required to be CSCC members; one should be the Head of the Education and Scientific Affairs Division, and one should be a CSCC Councillor if there is no conflict of interest. In awarding the grants, preference will be given to applicants who will be in their final year of study during the proposed visit and/or have not previously received a CSCC Trainee Elective Visit Grant. Whenever possible, grants will be distributed across two or more training programs each year. The reviewers complete scoring sheets and submit them to Head Office (info@cscc.ca). Head Office will notify applicants of the reviewer panel’s decision within one (1) month of receiving applications.

Updated and approved by Council, June 30, 2025.

Terms of Reference and Application Form

Download PDF

Terms of Reference

1. The Grant shall be presented to a member of the CSCC to support leadership and/or administrative contributions in the field of Clinical Chemistry or Pathology and Laboratory Medicine. This award is intended to encourage and support the administrative and leadership role of Laboratory Physicians and Scientists including (but not limited to):
a) administrative positions in hospitals, universities, private laboratories, government and
industry,
b) participation in committees of Provincial, National and International professional and
regulatory agencies,
c) leadership role in the strategic planning and implementation of laboratory services.

2. The applicant is to submit an online application via the CSCC website for consideration by the Awards Committee. Applicants will have to submit with their application a statement explaining why this grant is required, and a proposed budget. If their employer provides funds for education and travel, the candidates shall explain why these funds cannot be used for the purpose requested.

3. The deadline for applications is November 30 each year. Preference is to award the grant for an activity occurring in the award year that has not yet occurred. Exceptions may be considered by the Awards Committee with approval by Council.

4. The Grant shall usually be presented annually, but if in the opinion of the Awards Committee no suitable candidate(s) is available in any year, the Grant shall not be made. A maximum of three grants shall be given in any fiscal year. If the grant has not been awarded, the grant may remain open for the remainder of the award year.

5. Recipients of the Grant shall receive a maximum of $3,000, sponsored by CSCC Council.

6. Awarding of this grant is subject to available funds from the CSCC. Grant monies may be reduced, or the grant may not be funded in any given year, at the discretion of the Council.

7. The Awards Committee shall choose the recipient of the Award.

8. The Awards Committee shall report its choice to the Council of the Society not later than January 15 in the year for which the Grant is made.

9. The President of the Society will notify the recipient(s) of the Grant not later than March 1 in the year in which the Grant is made.

10. The recipient of the Grant is not usually expected to give an address or present a paper, but the Grant and the reading of the citation shall usually be made at the Annual Conference of the Society.

11. Proposals shall be solicited annually in the Newsletter of the Society.

12. The amendment of these Terms of Reference is the responsibility of the Council and should be reviewed at least every five years.

CSCC Grant for Leadership Application Form

Download Trainee Grant TOR

Participation in the Annual Conference of the CSCC provides trainees in laboratory medicine with a valuable opportunity to increase their knowledge in laboratory medicine and related fields, to discuss their work with colleagues, and to establish novel collaborative relationships.

CSCC provides a limited number of Trainee Travel Grants each year in support of this important facet of laboratory medicine training. Trainees are encouraged to apply for these grants if they meet all the following criteria:

1. They are members of the CSCC.
2. They are enrolled EITHER in a CACB-accredited clinical biochemistry training program OR in a Royal College of Physicians and Surgeons of Canada-accredited medical biochemistry training program.
3. They are presenting work at the Annual Conference of the CSCC that they performed during their current traineeship.

In awarding the travel grants, the CSCC Awards Committee will consider the following additional criteria:

1. Preference will be given to trainees:

• In their final year of study
• Who have not previously received a CSCC Trainee Travel Grant, AND
• Who reside outside of the city where the conference is being held.

2. Abstracts will be evaluated based on the amount of work involved in the study and the applicability of the results to the practice of Clinical/Medical Biochemistry. Preference will be given to clinical and analytical abstracts, followed by basic research.
3. Whenever possible, grants will be distributed across two or more training programs.

Trainees must send ALL the following information to CSCC Head Office (info@cscc.ca) to be considered for this Grant:

1. Name and institution of their training program,
2. Current year of training,
3. A copy of their submitted abstract, AND
4. Proof of acceptance of the abstract for presentation (Submitted within two weeks of notification of acceptance of abstract(s) by the conference organizing committee). Applicants will be notified by Head Office as soon as possible after all received travel grant applications have been reviewed.

Updated and approved by CSCC Council, June 30, 2025.

CSCC Grant for Educational Activities

1. The Grant(s) shall be presented to a Full member of the CSCC to support their educational activities and/or development of the profession in the field of Clinical Chemistry or Pathology and Laboratory Medicine. The grant is intended to encourage and support members who require additional funding, beyond that provided by their employer, to attend national/international conferences, take additional courses, or participate in other educational activities and professional development including (but not limited to): a. Attendance at the CSCC annual meeting or another national or international meeting relevant to laboratory medicine b. Visiting other laboratories to obtain specialized expertise in areas of laboratory medicine c. Attendance at provincial, national, or international courses, workshops, task forces or committees that promote professional development in laboratory medicine.
2. This grant is not intended to cover examination fees or related expenses
3. The applicant is to submit an online application via the CSCC website for consideration by the Awards Committee. Candidates will submit with their application a statement explaining why this grant is required, and a proposed budget. If their employer provides funds for education and travel, the candidates shall explain why these funds cannot be used for the purpose requested.
4. The deadline for applications is November 30 each year. Preference is to award the grant for an activity occurring in the award year that has not yet occurred. Exceptions may be considered by the Awards Committee with approval by Council.
5. The grant shall usually be presented annually, but, if in the opinion of the Awards Committee, no suitable candidate is available, the grant shall not be made. A maximum of three awards shall be given in any fiscal year. If the grant has not been awarded, the grant may remain open for the remainder of the award year.
6. Recipients of the grant shall receive a maximum of $3000, sponsored by the CSCC Council.  Awarding of this grant is subject to available funds from the CSCC.  Grant amounts may be reduced, or the grant may not be funded in any given year, at the discretion of the Council.
7. The Awards Committee shall choose the recipient(s) of the grant.
8. The Awards Committee shall report its choice(s) to the Council at the Winter Council meeting in the year for which the grant is made.
9. The President of the Society will notify recipient(s) not later than March 1 in the year in which the grant is made.
10. Grant recipients must provide a full accounting of expenses not more than sixty days following completion of the funded activity.
11. The recipient(s) is not usually required to give an address or paper, but the grants will be announced and the awardee(s) recognized at the Annual Meeting of the Society.
12. The amendment of the Terms of Reference is the responsibility of the Council., The terms of reference should be reviewed every five years.

CSCC Grant for Education Application Form

CSCC REGIONAL GRANT TOR

PROVINCIAL EDUCATION GRANTS Purpose

The purpose of Provincial Education Grants is to assist provincial societies with the provision of educational activities for their members. To further this goal, funding is allocated in advance to each provincial section so that they can plan events with the assurance that funds will be available. Funds will only be disbursed following the actual event. Amount of Grant: up to a maximum of $1,000 payable upon receipt of invoices

PROCEDURE

1. Application for the grant is to be made to CSCC Head Office and the Head of the Education and Scientific Affairs Division (ESAD) with supporting documentation of the event in the form of copies of the program and a proposed budget.
2. Request for reimbursement must be received at CSCC Head Office by November 30 of the year in which the event occurred.
3. If a host does not have the ability to fund an event, application for an advance may be made to the Head ESAD. At the discretion of the Head and the Treasurer, funds can be advanced on the understanding that documentation of how the funds were used will be provided after the event takes place.

Approved June 2015

CSCC REGIONAL GRANT APPLICATION FORM